title: Thermochemotherapy in adjuvant treatment of primary high risk non muscle invasive bladder cancers: Single center results.
abstract: OBJECTIVE
  To evaluate the results of Thermochemotherapy in adjuvant treatment of primary high risk non-muscle invasive bladder cancer in our center.
  
  
  METHODS
  The study included 26 patients with an age of 51-78 years (mean: 62.4 years). All patients had transurethral tumor resection (TURB) after being diagnosed with a primary bladder tumor and were pathologically diagnosed with non-muscle invasive urothelial carcinoma. Thermochemotherapy (TCT) applications were performed via the Synergo® system SB-TS 101.
  
  
  RESULTS
  Of the study participants, 13 patients had T1 Grade III, six patients had T1Grade III CIS (+), four patients had Ta Grade III, and three patients Ta Grade II multiple > 5 cm tumor. In all patients, six weeks plus six months protocol were completed. All patients completed the follow-up protocol. With a median follow-up time of 16.4 months (range: 6 - 48 months), recurrent urothelial carcinoma was identified in three patients. With a median follow-up time of 16.4 months, the recurrence-free survival was 88.4% in 26 patients included in the study.
  
  
  CONCLUSIONS
  The obtained data suggest that the TCT method can be used effectively and safely in non-muscle invasive bladder cancers of primary high-risk. Prospective randomized studies will shed light on this subject which are BCG vs TCT in primary high risk patients and second course BCG vs TCT in the BCG insufficient patients.
authors.affiliation: University of Gaziantep, School of Medicine, Department of Urology, Gaziantep, Turkey.
authors.forename: Sakip
authors.initials: S
authors.lastname: Erturhan
authors.affiliation: University of Gaziantep, School of Medicine, Department of Urology, Gaziantep, Turkey.
authors.forename: Haluk
authors.initials: H
authors.lastname: Sen
authors.affiliation: University of Gaziantep, School of Medicine, Department of Urology, Gaziantep, Turkey.
authors.forename: Asaf
authors.initials: A
authors.lastname: Demirbag
authors.affiliation: University of Gaziantep, School of Medicine, Department of Urology, Gaziantep, Turkey.
authors.forename: Omer
authors.initials: O
authors.lastname: Bayrak
authors.affiliation: University of Gaziantep, School of Medicine, Department of Urology, Gaziantep, Turkey.
authors.forename: Faruk
authors.initials: F
authors.lastname: Yagci
authors.affiliation: University of Gaziantep, School of Medicine, Department of Urology, Gaziantep, Turkey.
authors.forename: Iker
authors.initials: I
authors.lastname: Seckiner
authors.affiliation: University of Gaziantep, School of Medicine, Department of Urology, Gaziantep, Turkey.
authors.forename: Ahmet
authors.initials: A
authors.lastname: Erbagci
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D012307:Risk Factors; D001749:Urinary Bladder Neoplasms / Q000473:pathology / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents